Neurogene (NGNE) Non Operating Investment Income (2020)
Neurogene's (NGNE) quarterly Non Operating Investment Income came in at $7.8 million in Q3 2020.
Powered by 
Analysis
Neurogene (NGNE) Non Operating Investment Income (2020) Analysis & Trends
Neurogene (NGNE) has 1 years of Non Operating Investment Income data on file, last reported at $7.8 million in Q3 2020.
- Quarterly Non Operating Investment Income changed N/A year-over-year to $7.8 million in Q3 2020, while the trailing twelve-month figure through Dec 2021 was $7.8 million (changed N/A YoY) and the FY2020 annual result came in at $7.8 million, changed N/A from the prior year.
- Non Operating Investment Income held at $7.8 million in Q3 2020.
- In the past five years, Non Operating Investment Income ranged from a high of $7.8 million in Q3 2020 to a low of $7.8 million in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Neurogene | 864.53 Mn | 864.53 Mn | - | - |